About CarePath Biologics
Advancing the Frontier of Biologic Therapies
CarePath Biologics is relentlessly committed to maximizing therapeutic potential by harnessing the power of human biology to treat patients suffering from degenerative disease, damaged tissue, injury, and trauma. As one ages, the body’s ability to repair and remodel decreases. Employing innovative science, CarePath Biologics is discovering and developing breakthrough therapeutics that optimize the repair process and lead to organized scar free advanced healing. Our novel approach begins with a platform of naturally advanced human biological material from which we unravel the code of complex molecules, isolating and applying them to treat a multitude of conditions. Targeted therapies under development have the power to help upwards of 50 million patients per year.
Future Biologics
Addressing a $100 billion market, CarePath Biologics is rapidly advancing multiple future regenerative biological therapies that will target all areas of the musculoskeletal system, internal tissue structures and areas where there is a high-unmet medical need and leverages its platform and expertise. We are dedicated and strive to accelerate to market regenerative solutions that improve health outcomes and dramatically improve people’s lives. A biotech leader since 2010, CarePath Biologics has grown to be one of the world’s leading independent new age biotechnology companies, has reached hundreds of thousands of patients in the US with existing tissue products and is developing a pipeline of medicines with breakaway potential for decades to come.
Active & Future Clinical Trials:
Orthopedic / Sports Medicine / Spine / Foot & Ankle / Wounds / Urology & Gynecology
Learn About our Purpose & Commitment to Improving Patient Quality of Life
CarePath Biologics first generation tissue implants have been used in over 250,000 tissue-repair treatments nationwide, to augment and support degenerated or damaged tissues in surgical repairs and non-operative therapy as a potential alternative to surgery.
Our implants performance utilizes a complex BioActive® scaffold. The source of our implants and biologics are derived from a unique and very promising age-zero human biologic material, which has is immune privileged material and immense remodeling potential.
Our current and future therapeutic product offering provides biologic solutions with ideal handling and delivery options for most clinical challenges, and applications for this technology are continually increasing. When these future therapeutics are applied, they provide a native scaffold structure along with abundant growth factors and BioActive® molecules that support and restore the body’s remodeling ability.
The current tissue transplants and future therapeutic biologics will be utilized in the treatment of musculoskeletal injuries, nerve grafting, scar and adhesion prevention, incision and wound repair, and other applications in orthopaedic, podiatry, neuro and spine, GYN, urologic, colorectal, general, head, and neck, ocular and wound care procedures.
CarePath Biologics continues to work together with leading physicians, institutions, hospitals, and corporate partners to identify medical needs and continue to develop and tailor our advanced BioECM® transplant grafts and future biologic therapeutics.